Business Wire

NetWitness Launches Comprehensive XDR Offerings for Next Generation Security

7.6.2022 19:00:00 EEST | Business Wire | Press release

Share

NetWitness, a globally trusted provider of cybersecurity technologies and incident response, today announced NetWitness XDR, a family of products and capabilities delivering comprehensive detection and response on premise, in the cloud or as a hybrid of the two. This new offering and product architecture delivers the full range of deployment options enterprises seek today to meet their unique cybersecurity needs and use cases.

NetWitness XDR delivers a robust set of capabilities enabling extended detection and response (XDR) and helping customers stay ahead of the most sophisticated cyber threats. These include:

  1. Unified collection, data, and visibility across multiple security layers
  2. Automatic enrichment of data using any technical or business source
  3. A wide toolset of detection technologies including, but not limited to, advanced behavioral analysis
  4. External and internal threat intelligence to identify known security risks and threat actors
  5. Truly insightful context, visualization, and investigation tools
  6. Threat hunting tools and methodologies to identify previously unknown threats
  7. Highly repeatable and measurable incident investigation and response processes
  8. A strong array of both automated and human response options

“NetWitness has enjoyed the trust of some of the world’s most security sensitive organizations because of its unique ability to monitor the entire attack surface across the network, endpoint, cloud, IoT, logs and more,” said CEO of RSA and NetWitness, Rohit Ghai. “We have been delivering XDR capability to the market for several years and today we are delighted to announce new innovations in the platform and reintroduce it to the market as NetWitness XDR.”

Under this new model, NetWitness XDR will be comprised of three main product lines that showcase its uniquely powerful support for all XDR use cases. NetWitness Platform XDR 12 is the newest major release of NetWitness Platform. This technology stack, typically deployed as customer-managed software or hosted by MSSPs, has been enhanced to focus on detection capabilities that identify threats faster and decrease their impact. The company’s new cloud-native SaaS version will be known as NetWitness Vision XDR and is currently in design preview. The third product line, NetWitness XDR Cloud Services, is a set of optional SaaS applications that take advantage of the cloud’s inherent elastic nature to deliver flexible and cost-effective components which can be used to augment either Platform XDR or Vision XDR.

“Our network-forward approach allows us to stand out in this emerging space and highlights NetWitness XDR’s ability to detect across customers’ growing number of systems and devices,” said Director of Product Management and Research, Kevin Bowers. “We are embracing the belief that the best XDR must be consumable on prem, in the cloud, and hybrid.”

Developed initially in 1996, NetWitness began as a government-sponsored research project to inspect network packets for cyberthreats and tools to detect and respond to them. Since then, the technology has continuously evolved and been innovated to tackle today’s most complex attacks. NetWitness now features fully integrated components for network, log, endpoint and IoT detection and response that drive its threat intelligence and security orchestration platform, NetWitness Orchestrator. With its long history and global footprint, NetWitness XDR integrates directly with the world’s most critical and widely deployed tools, as well as many specialized and industry-specific solutions.

NetWitness XDR will host demonstrations at its booth at RSA Conference this year for Platform XDR and Vision XDR.

To learn more, visit www.netwitness.com.

ABOUT NetWitness

NetWitness, an RSA® Group Business, provides comprehensive and highly scalable threat detection and response capabilities for organizations around the world. The NetWitness Platform delivers complete visibility combined with applied threat intelligence and user behavior analytics to detect, prioritize, investigate threats, and automate response. This empowers security analysts to be more efficient and stay ahead of business-impacting threats. For more information, visit netwitness.com.

©2022 RSA Security LLC or its affiliates. All rights reserved. RSA and the RSA logo are trademarks of RSA Security LLC or its affiliates. For a list of RSA trademarks visit https://www.rsa.com/en-us/company/rsa-trademarks . Other trademarks are trademarks of their respective owners. RSA believes the information in this document is accurate. The information is subject to change without notice.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

SHIFT Communications
netwitness@shiftcomm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye